Morrison Briggs's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Mar 14, 2023
- Accession no.
- 0001562180-23-002770
- Filed
- Mar 14, 2023
- Trade date
- Mar 13, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.19M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morrison BriggsCIK 0001654430 | Director, Officer (President, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2023 | Common Stock | MOption exerciseAcquired | +52,854 | $6.38 | +$337,208.52 | 70,690 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −52,854 | $22.53 | −$1,190,800.62 | 17,836 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2023 | Common Stock | MOption exerciseDisposed | −52,854 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.